Yang (Carsten) Lu, Adlai Nortye CEO

With its ex-No­var­tis can­cer drug near the fin­ish line, Ad­lai Nortye rais­es $97.5M in Nas­daq de­but

The Nas­daq is wel­com­ing an­oth­er com­pa­ny hus­tling along a late-stage drug, with Ad­lai Nortye rais­ing $97.5 mil­lion from an IPO and a con­cur­rent pri­vate place­ment.

Ad­lai Nortye li­censed its lead pro­gram, the PI3K in­hibitor bu­parlis­ib, from No­var­tis back in 2018 and has since steered it in­to a Phase III tri­al for squa­mous cell car­ci­no­ma of the head and neck. Its sec­ond drug, now in Phase Ib, was li­censed from Ei­sai, and the pipeline fea­tures one more clin­i­cal pro­gram and three pre­clin­i­cal ones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.